Diagram of retatrutide triple-receptor agonism at the GLP-1, GIP, and glucagon receptors

What Is Retatrutide? A Research Guide to the Triple-Receptor Peptide

Retatrutide — the investigational triple agonist available as a research-grade Retatrutide peptide — has become one of the most-discussed compounds in metabolic pharmacology, after clinical trial data reported some of the largest body-weight reductions recorded for any incretin-class molecule. So what is retatrutide, and what makes it pharmacologically distinct? The short answer: it is an investigational triple receptor agonist developed by Eli Lilly under the code LY3437943, engineered to activate the GLP-1, GIP, and glucagon receptors at once. The longer answer — covering structure, mechanism, the trial evidence base, and research context — is below.

This guide is written for laboratories and researchers working with the compound. Reta Labs supplies retatrutide as a research-grade material at ≥99% HPLC purity with mass-spectrometry-verified identity, a batch-specific certificate of analysis, and domestic Canadian shipping. It is sold strictly for research use only.

Table of Contents

What Is Retatrutide? Definition and Overview

Retatrutide is an investigational research peptide developed by Eli Lilly under the code LY3437943, classified pharmacologically as a triple agonist of the GLP-1, GIP, and glucagon receptors. It is the first triple receptor agonist in the metabolic peptide category to reach Phase 3, where it is being studied across multiple indications in Eli Lilly's TRIUMPH program. It remains investigational and is not approved for human use by any regulator.

Several features set retatrutide apart from earlier incretin-class compounds:

  • Triple receptor activity. Where semaglutide engages only the GLP-1 receptor and tirzepatide engages GLP-1 and GIP, retatrutide adds a third target — the glucagon receptor — a metabolic dimension earlier incretin compounds did not reach.
  • Balanced agonism. Its three-receptor activity is engineered to be balanced rather than dominated by one receptor, which is what allows research designs to study integrated metabolic effects rather than single-mechanism activity.
  • Extended half-life. Structural modifications (Aib substitutions and C20 fatty-diacid acylation) extend circulation time through albumin binding, supporting the once-weekly schedule used in the clinical trials that have studied it.
  • Growing evidence base. Though newer than semaglutide or tirzepatide, retatrutide now has both Phase 2 and Phase 3 data alongside an expanding preclinical literature across metabolic, hepatic, and energy-expenditure endpoints.

Molecular Structure and Design

Understanding what retatrutide is at the molecular level means looking at the structural choices that make its three-receptor profile possible. Retatrutide is a 39-amino-acid peptide built through several deliberate modifications:

  • Backbone sequence. The peptide backbone is related to the glucagon hormone family, providing the template that engages incretin and glucagon receptors. The sequence was optimised through structure–activity studies to balance affinity across all three target receptors.
  • Aib (α-aminoisobutyric acid) substitutions. Non-natural Aib residues at two backbone positions protect vulnerable peptide bonds from dipeptidyl peptidase-IV (DPP-4) cleavage — the enzyme that rapidly degrades native GLP-1. Without this resistance, peptides in this class would circulate for minutes rather than days.
  • C20 fatty-diacid acylation. A 20-carbon fatty diacid attached via a γ-glutamic acid linker enables reversible binding to serum albumin, which extends circulation half-life and provides a depot effect — reported at roughly six days, consistent with once-weekly dosing in trials.
  • Balanced receptor affinity. Rather than favouring one receptor, retatrutide is tuned for comparable activity across GLP-1, GIP, and glucagon receptors. This balance is the central design innovation distinguishing it from earlier incretin compounds.

How Does Retatrutide Work? Triple Receptor Agonism

Retatrutide's mechanism centres on activating three receptors that each contribute distinct metabolic effects. Understanding this triple agonism is key to understanding what makes the compound pharmacologically distinct.

GLP-1 receptor activation

The GLP-1 receptor is found on pancreatic β-cells, hypothalamic and brainstem neurons, and cells throughout the gastrointestinal tract. In research, GLP-1 receptor activation is associated with:

  • Glucose-dependent insulin secretion from β-cells, supporting glycemic regulation without hypoglycemia at normal glucose levels
  • Glucagon suppression from α-cells, reducing hepatic glucose output
  • Slowed gastric emptying, blunting postprandial glucose excursions
  • Central appetite signalling through hypothalamic and brainstem receptors

This is the component that semaglutide-class compounds rely on; retatrutide preserves it while adding two further mechanisms.

GIP receptor activation

The GIP (glucose-dependent insulinotropic polypeptide) receptor appears on β-cells, adipocytes, and CNS neurons. In research it is associated with:

  • Amplified insulin secretion beyond GLP-1 alone
  • Adipose-tissue modulation affecting fat storage and substrate handling
  • Central satiety signalling that complements GLP-1's central effects
  • Bone-metabolism effects through receptors on bone tissue

GIP agonism was once considered counterproductive, but research with tirzepatide indicated that dual GLP-1/GIP activation produces effects beyond GLP-1 alone — an advantage retatrutide retains.

Glucagon receptor activation

The glucagon receptor sits mainly on hepatocytes and adipocytes, with smaller populations in heart and kidney. In research, its activation is associated with:

  • Hepatic lipid mobilisation through stimulation of hepatic fatty-acid oxidation
  • Lipolysis in adipose tissue, mobilising stored triglycerides
  • Increased energy expenditure via effects on brown adipose tissue and hepatic substrate cycling
  • Hepatic glucose output (the classical glucagon effect, offset by GLP-1's insulin-stimulating activity)

The glucagon component is what most clearly distinguishes retatrutide from semaglutide and tirzepatide. The design challenge — balancing glucagon's glucose-raising effect against its metabolic contributions — was addressed by tuning the GLP-1/GIP/glucagon ratio so that sufficient GLP-1 activity offsets hepatic glucose output.

For a deeper treatment of how these three pathways interact, see our companion explainer on GLP-1 vs GIP vs glucagon agonism.

Clinical Development Timeline

Retatrutide's timeline clarifies where the compound sits today.

  • Pre-2020 — preclinical development. Eli Lilly's metabolic-peptide program advanced through dual agonists (producing tirzepatide) before exploring triple-receptor combinations.
  • 2020 — first clinical disclosure. LY3437943 was disclosed in trial registries as an investigational triple agonist.
  • 2022 — Phase 1 completion. Safety and pharmacokinetic studies established the parameters used in Phase 2.
  • 2023 — Phase 2 results. The pivotal Phase 2 obesity trial was published in The New England Journal of Medicine, reporting dose-dependent body-weight reductions of roughly 24% at 48 weeks at the highest dose.
  • 2025–2026 — Phase 3 readouts. The Phase 3 TRIUMPH program (begun 2023, enrolling several thousand participants across obesity, type 2 diabetes, MASH, and cardiovascular indications) began reporting: TRIUMPH-4 posted positive topline results in December 2025, and TRIUMPH-1 reported topline obesity results in May 2026. Additional readouts are expected through 2026 and beyond.
  • Current status. Retatrutide remains investigational. It is not approved by the FDA, EMA, or any other regulator; a regulatory filing is not expected before late 2026, with any approval realistically no sooner than 2027. All current use is research-use-only.

Trial Evidence Base: Phase 2 and Phase 3

For researchers evaluating the evidence base, the published and announced trial data deserve a closer look — reported here as study findings, not as outcomes associated with any use of the material.

Phase 2 (2023)

The Phase 2 obesity trial enrolled 338 participants and tested four doses (1, 4, 8, and 12 mg) administered once weekly for 48 weeks against placebo. As published in The New England Journal of Medicine, mean body-weight reductions at 48 weeks were reported as approximately 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg), versus about 2.1% for placebo. The trial also reported reductions in HbA1c among participants with elevated baseline glucose, improvements in cardiometabolic markers, and reductions in imaging-measured liver fat. Adverse events were consistent with the incretin class, primarily dose-dependent gastrointestinal effects. A separate Phase 2 trial in type 2 diabetes, published in The Lancet, reported effects of similar magnitude on glycemic markers and body weight.

Phase 3 (2025–2026)

The Phase 3 TRIUMPH program has since reported confirmatory data. TRIUMPH-4 announced positive topline results in December 2025. TRIUMPH-1 — a roughly 2,300-participant, 80-week obesity trial testing 4, 9, and 12 mg — reported in May 2026 that the 12 mg dose was associated with mean weight reductions near 28% over 80 weeks, with a substantial proportion of participants reaching the higher response thresholds; an extension reported further reductions at 104 weeks. These Phase 3 readouts broadly reinforced the Phase 2 trajectory at larger scale. The compound nevertheless remains investigational pending completion of the wider program and regulatory review.

Research Applications

For laboratories investigating metabolic biology, retatrutide's three-receptor pharmacology supports several distinct research applications.

Triple-receptor pharmacology

The most distinctive application is investigating what triple agonism contributes beyond single or dual mechanisms. Comparative designs commonly position retatrutide against semaglutide (GLP-1-only reference), tirzepatide (dual GLP-1/GIP reference), and selective single-receptor agonists for mechanism deconvolution — allowing specific effects to be attributed to specific pathways.

Hepatic lipid biology

The glucagon component makes retatrutide useful in research on hepatic lipid metabolism — an area GLP-1-only and dual agonists cannot directly address. Applications include NAFLD and MASH model investigation, hepatic fatty-acid-oxidation pathway research, and liver-specific metabolic phenotyping.

Energy expenditure

Because glucagon-receptor activation is associated with increased resting metabolic rate, retatrutide serves as a tool for studying the energy-expenditure side of body-composition regulation — including brown-adipose thermogenesis, mitochondrial uncoupling, and energy-balance designs.

Integrated metabolic-syndrome research

Because it simultaneously influences glucose handling, lipid profiles, and hepatic function, retatrutide supports designs that study metabolic syndrome as an integrated phenomenon rather than as isolated components. Groups working across the metabolic research peptide cluster often position it alongside related compounds — such as MOTS-c for mitochondrial energy signalling, Tesamorelin for the GHRH axis, and HGH Fragment 176-191 for isolated lipid-metabolism questions — each approaching the same biology from a different mechanistic angle.

How Retatrutide Compares to Other Incretin Peptides

What retatrutide is becomes clearer alongside related incretin-class compounds.

Compound Receptor Targets Reported Max Weight Reduction Regulatory Status
Semaglutide GLP-1 only ~15% Approved (Ozempic, Wegovy)
Liraglutide GLP-1 only ~8% Approved (Victoza, Saxenda)
Tirzepatide GLP-1 + GIP ~22% Approved (Mounjaro, Zepbound)
Retatrutide GLP-1 + GIP + Glucagon ~28% (Phase 3) Investigational (Phase 3)

The progression from single agonist to dual agonist to triple agonist reflects increasing pharmacological complexity, with each added receptor reaching biology the previous step could not:

  • GLP-1 alone — appetite signalling and glucose-dependent insulin secretion
  • GLP-1 + GIP — enhanced insulin amplification, adipose modulation, central satiety
  • GLP-1 + GIP + glucagon — hepatic lipid mobilisation, lipolysis, energy expenditure

Retatrutide sits at the current frontier of this pattern, with research groups now exploring further receptor combinations (amylin, FGF21, GDF15) that may extend it.

Sourcing Retatrutide for Canadian Research

Sourcing retatrutide as a research compound calls for attention to quality and supply-chain factors that affect reproducibility.

Manufacturing and verification. Research-grade retatrutide should carry ≥99% HPLC purity verification per batch, mass-spectrometry identity confirmation, batch-specific certificates of analysis, and documented manufacturing oversight.

Canadian sourcing advantages. For Canadian labs, domestic sourcing reduces customs delays, shortens shipping to support cold-chain integrity, and provides direct supplier accountability — practical benefits over international suppliers.

Documentation and storage. Designs under institutional or audit requirements benefit from lot-traceable COAs, HPLC chromatograms, and MS spectra. As an acylated peptide, retatrutide is typically stored refrigerated (2–8 °C) for short-term laboratory use or frozen for longer-term storage, protected from light, following each lab's own handling protocols.

Reta Labs supplies Retatrutide research peptide at ≥99% HPLC purity with MS-verified identity, batch-specific COAs, and fast domestic Canadian shipping, alongside a wider range of metabolic research peptides. The compound is sold strictly for research use only.

Frequently Asked Questions

What is retatrutide used for in research?

Retatrutide is used in research designs investigating triple receptor agonism in metabolic biology — the combined effects of GLP-1, GIP, and glucagon receptor activation. Applications include integrated metabolic regulation, hepatic lipid biology, and energy-expenditure mechanisms. It is sold strictly for laboratory research use only and is not approved for human use.

Is retatrutide the same as Ozempic or Mounjaro?

No. All three are incretin-class peptides, but they differ by mechanism. Semaglutide (Ozempic, Wegovy) activates only GLP-1. Tirzepatide (Mounjaro, Zepbound) activates GLP-1 and GIP. Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, giving it a different pharmacological profile.

How does retatrutide compare to tirzepatide?

Both are multi-receptor incretin agonists, but retatrutide adds glucagon-receptor activation to tirzepatide's dual GLP-1/GIP activity. In reported trial data, retatrutide has been associated with larger body-weight reductions, and its glucagon activity opens research applications in hepatic lipid biology and energy expenditure that dual agonists cannot directly study.

What is the difference between retatrutide and glucagon?

Glucagon is an endogenous 29-amino-acid hormone that raises blood glucose. Retatrutide is a synthetic 39-amino-acid peptide that activates the glucagon receptor as one of three targets. The key distinction is that retatrutide's simultaneous GLP-1 activation offsets glucagon's glucose-raising effect, so the other glucagon-associated mechanisms (lipolysis, energy expenditure, hepatic lipid mobilisation) can be studied without the same glycemic trade-off.

What mechanisms underlie retatrutide's effects on body composition in research?

In published studies, retatrutide's body-composition effects have been attributed to several converging mechanisms: central appetite signalling through GLP-1 and GIP receptors, slowed gastric emptying, lipolysis and hepatic fatty-acid oxidation through glucagon-receptor activation, and increased resting metabolic rate. The combination of reduced energy intake and increased energy expenditure is the proposed basis for the magnitude of the reductions reported in trials.

Where can researchers source retatrutide in Canada?

Canadian labs should look for ≥99% HPLC purity confirmation per batch, mass-spectrometry identity verification, and domestic shipping to avoid cold-chain interruptions. Reta Labs supplies Retatrutide for research use only, with batch-specific COAs, MS-verified identity, and fast domestic Canadian shipping.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.

Back to blog